TELA Bio (TELA) Projected to Announce Quarterly Earnings on Tuesday

TELA Bio (NASDAQ:TELA) is projected to announce its Q3 2026 resultson Tuesday, November 10th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $20.00 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

TELA Bio (NASDAQ:TELA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $19.29 million during the quarter, compared to the consensus estimate of $20.01 million. TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%. On average, analysts expect TELA Bio to post ($0.76) EPS for the current fiscal year and ($0.44) EPS for the next fiscal year.

TELA Bio Trading Up 6.2%

TELA Bio stock traded up $0.05 during trading hours on Tuesday, hitting $0.85. 2,671 shares of the stock traded hands, compared to its average volume of 181,736. TELA Bio has a one year low of $0.50 and a one year high of $1.50. The company has a market cap of $38.33 million, a PE ratio of -1.10 and a beta of 1.36. The firm’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $0.86.

Insider Activity at TELA Bio

In other TELA Bio news, Director Joseph Capper purchased 25,000 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was purchased at an average price of $1.22 per share, for a total transaction of $30,500.00. Following the completion of the purchase, the director directly owned 179,827 shares of the company’s stock, valued at $219,388.94. This trade represents a 16.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders acquired 115,000 shares of company stock valued at $119,500. 1.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on TELA shares. Wall Street Zen upgraded TELA Bio to a “sell” rating in a report on Saturday. Weiss Ratings raised shares of TELA Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. UBS Group set a $2.00 price objective on shares of TELA Bio in a research report on Friday, September 25th. Finally, Craig Hallum started coverage on shares of TELA Bio in a research note on Friday, September 25th. They set a “buy” rating and a $2.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $2.14.

TELA Bio Company Profile

TELA Bio, Inc is a medical technology company that develops and commercializes advanced tissue-reinforcement products for soft-tissue repair and reconstruction. The company’s products are designed to support the repair of damaged or weakened tissue while preserving a more natural tissue response.

TELA Bio’s principal product platform is OviTex Reinforced Tissue Matrix, which combines biologic tissue with polymer reinforcement in a proprietary, textile-like design. OviTex products are used in procedures involving hernia and abdominal wall repair, as well as other soft-tissue reconstruction applications.